DE60115872D1 - Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom - Google Patents

Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom

Info

Publication number
DE60115872D1
DE60115872D1 DE60115872T DE60115872T DE60115872D1 DE 60115872 D1 DE60115872 D1 DE 60115872D1 DE 60115872 T DE60115872 T DE 60115872T DE 60115872 T DE60115872 T DE 60115872T DE 60115872 D1 DE60115872 D1 DE 60115872D1
Authority
DE
Germany
Prior art keywords
cabergolin
fibromyalgia
treatment
chronic fatigue
fatigue syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60115872T
Other languages
English (en)
Other versions
DE60115872T2 (de
Inventor
B Mccall
C Marshall
W Robertson
M Ashley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Publication of DE60115872D1 publication Critical patent/DE60115872D1/de
Application granted granted Critical
Publication of DE60115872T2 publication Critical patent/DE60115872T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE60115872T 2000-04-21 2001-04-17 Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom Expired - Fee Related DE60115872T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19895900P 2000-04-21 2000-04-21
US198959P 2000-04-21
US20056900P 2000-04-28 2000-04-28
US200569P 2000-04-28
PCT/US2001/010807 WO2001081343A2 (en) 2000-04-21 2001-04-17 Compounds for treating fibromyalgia and chronic fatigue syndrome

Publications (2)

Publication Number Publication Date
DE60115872D1 true DE60115872D1 (de) 2006-01-19
DE60115872T2 DE60115872T2 (de) 2006-07-13

Family

ID=26894316

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60115872T Expired - Fee Related DE60115872T2 (de) 2000-04-21 2001-04-17 Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom

Country Status (16)

Country Link
US (3) US6448258B2 (de)
EP (1) EP1274430B1 (de)
JP (1) JP2004502650A (de)
KR (1) KR20040007215A (de)
CN (3) CN1450898A (de)
AR (3) AR028355A1 (de)
AT (1) ATE312608T1 (de)
AU (2) AU5311401A (de)
BR (1) BR0110210A (de)
CA (1) CA2405565A1 (de)
DE (1) DE60115872T2 (de)
DK (1) DK1274430T3 (de)
ES (1) ES2253370T3 (de)
NZ (3) NZ531172A (de)
PE (1) PE20011212A1 (de)
WO (1) WO2001081343A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2404704A1 (en) * 2000-04-21 2001-11-22 David W. Robertson Treatment of fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
MXPA03001472A (es) * 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
CA2500919A1 (en) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
BR0314526A (pt) * 2002-10-04 2005-07-26 Pharmacia Corp Composições farmacêuticas para o tratamento do mal de parkinson
JP2009501184A (ja) 2005-07-13 2009-01-15 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６、５−ｈｔ２４としてのベンゾイミダゾール誘導体
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
ES2332645B1 (es) * 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
DK2618826T3 (en) * 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
DE102014008742A1 (de) * 2014-06-12 2015-12-17 Daimler Ag Separator für einen elektrochemischen Speicher, Verfahren zur Herstellung eines Elektrodenmaterials sowie elektrochemischer Energiespeicher
EP3194406B8 (de) 2014-09-15 2021-03-31 Incyte Corporation Tricyclische heterocyclen zur verwendung als bet-protein-hemmer
WO2016180879A1 (en) * 2015-05-13 2016-11-17 A. Carlsson Research Ab Treatment of debilitating fatigue
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CR20220651A (es) 2016-06-20 2023-01-23 Incyte Corp FORMAS SOLIDAS CRISTALINAS DE UN INHIBIDOR DE BET (Divisional expediente 2019-0027.)
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
EP0641320B1 (de) * 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
AU684808B2 (en) * 1993-07-27 1998-01-08 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
JPH1053525A (ja) * 1996-06-06 1998-02-24 Bitakain Seiyaku Kk 疼痛治療剤
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
PT1459750E (pt) 1999-07-01 2005-08-31 Pharmacia & Upjohn Co Llc (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
WO2001015677A2 (en) 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain

Also Published As

Publication number Publication date
US6555548B2 (en) 2003-04-29
JP2004502650A (ja) 2004-01-29
US6448258B2 (en) 2002-09-10
CN1554343A (zh) 2004-12-15
EP1274430B1 (de) 2005-12-14
NZ531171A (en) 2005-03-24
US20020004510A1 (en) 2002-01-10
AU2001253114B2 (en) 2005-08-25
NZ531172A (en) 2005-07-29
CN1554341A (zh) 2004-12-15
DK1274430T3 (da) 2006-02-13
US20030191149A1 (en) 2003-10-09
KR20040007215A (ko) 2004-01-24
EP1274430A2 (de) 2003-01-15
CN1450898A (zh) 2003-10-22
NZ522112A (en) 2004-10-29
WO2001081343A3 (en) 2002-02-28
AU5311401A (en) 2001-11-07
BR0110210A (pt) 2003-01-28
ATE312608T1 (de) 2005-12-15
AR039633A2 (es) 2005-03-02
CA2405565A1 (en) 2001-11-01
AR039632A2 (es) 2005-03-02
US20020143010A1 (en) 2002-10-03
ES2253370T3 (es) 2006-06-01
DE60115872T2 (de) 2006-07-13
WO2001081343A2 (en) 2001-11-01
PE20011212A1 (es) 2001-11-21
AR028355A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
DE60115872D1 (de) Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
DE60035232D1 (de) (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
DE60012138D1 (de) Gerät zur behandlung von fibrillation
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
DE60215392D1 (de) Gerät mit reduzierten abmessungen und verbesserter ergonomie zur behandlung der oberfläche von objekten
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE50107279D1 (de) Autoklav zur präzisionsreinigung von stücken und verwendung des autoklavs
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee